MediClin AG (STU:MED) Moat Score: 0/10 (As of Jul. 08, 2026)


STU:MED MediClin AG STU:MED
76 GF Score
Price €3.88
GF Value €2.93
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is MediClin AG Moat Score?

MediClin AG has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

MediClin AG has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes MediClin AG might have No Moat - No discernible moat.

MediClin AG  (STU:MED) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

MediClin AG Moat Score Related Terms

STU:MED
76GF Score
MediClin AG STU:MED
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MediClin AG (STU:MED) Overvalued in 2026?

Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued. The current stock price of €3.88 is trading 32.4% above its estimated GF Value™ of €2.93. GuruFocus considers MediClin AG to be Significantly Overvalued.

Key valuation signals for STU:MED:

  • Moat Score: 0
  • GF Value™: €2.93 vs. price of €3.88 (32.4% above fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the STU:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MediClin AG Business Description

Other Exchanges 0NDG:UKMED:Germany
Address Okenstrasse 27, Offenburg, BW, DEU, 77652
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
76GF Score

Get the complete analysis for STU:MED

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.88
Price
€2.93
GF Value